Jin Medical International Ltd. — Form 6-K Summary
Business Context and Reporting Period
Jin Medical International Ltd., a foreign private issuer headquartered in Changzhou, Jiangsu Province, China, filed this Form 6-K for March 2024. The filing, dated March 29, 2024, reports developments concerning the Company’s Nasdaq listing compliance.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial operating metrics.
Material Changes and Nasdaq Listing Status
- On September 25, 2023, Nasdaq notified the Company that it was not in compliance with Listing Rule 5550(a)(3), which requires at least 300 public holders for continued listing.
- On February 29, 2024, Nasdaq informed the Company that it had regained compliance with the 300 public-holder requirement.
- The Company remained deficient under Listing Rule 5250(c) because it had not filed its annual report on Form 20-F for the fiscal year ended September 30, 2023.
- On March 28, 2024, the Nasdaq Hearings Panel granted continued listing, subject to the Company filing its fiscal 2023 Form 20-F with the SEC by May 20, 2024.
Outlook, Risks, and Unusual Items
The Company stated that it is preparing the annual report and plans to file it within the extension period. Continued Nasdaq listing is conditional on timely filing by May 20, 2024. Failure to meet this condition could result in renewed delisting action or loss of Nasdaq listing eligibility.
Key Facts for Investors to Verify
- Whether the Company filed its fiscal 2023 Form 20-F by May 20, 2024.
- Whether Nasdaq confirmed continued compliance after the filing.
- The financial results, liquidity position, and any additional disclosures contained in the fiscal 2023 Form 20-F.
- Whether any further Nasdaq deficiencies or listing conditions were imposed.